Kornimate/medical-research-clean huggingface dataset:
constitution of a biological collection to study the pathophysiology in noonan syndrome

Conditions: Noonan Syndrome

Summary: the present study will establish a collection of biological samples from noonan patients to be used for research purposes only, with due respect for confidentiality.

noonan syndrome is a rare autosomal dominant genetic disorder characterized by a combination of typical facial features, heart defects, short stature, skeletal abnormalities, mild developmental delay and a predisposition to myeloproliferative disorders. this syndrome is caused by germline mutations in genes encoding components or regulators of the rat sarcoma (ras) / extracellular signal-regulated kinase (erk) signaling pathway, which is essential for cell cycle differentiation, growth, and senescence. patients with noonan syndrome or related diseases are followed at the children's hospital, toulouse university hospital. during regular check-up visits, an extra sample of blood and urine will be collected and stored for research utilisation with the patient's consent. the ultimate objective of this collection is to provide available biological resources to facilitate the development of subsequent studies aimed at better characterizing the multisystemic disorders in noonan syndrome, to understand the pathophysiology of the disease, and to identify biological factors that predict the severity and progression of the disease. the possibility of having systematically collected biological resources will make it possible to answer certain questions more quickly depending on the progress of research.

Eligibility criteria:
inclusion criteria: * children aged at least 3 years old or adult with noonan syndrome * patients affiliated to or beneficiaries of a social security scheme * patients able to receive information on the progress of the study and understand the information form to participate in the study. that implies to master the french language and not to be subject to a restriction of rights by the judicial authorities * patients or legal representative who have given their consent to participate in the study (expression of no objection) exclusion criteria: * patients subject to a legal protection measure (guardianship, curators, or safeguard of justice) * pregnant or breastfeeding women

Keywords: biological collection noonan syndrome
the influence of radiotherapy on cognitive function

Conditions: Radiotherapy; Brain Neoplasms; Quality of Life

Summary: the cognitive function of 150 patients that undergone any radiotherapy treatment to the brain will be assessed at 3 time points before and after the treatment.

the basic cognitive function and qol of 150 oncologic patients that undergone radiotherapy or radiosurgery treatment to the brain due to primary tumor, metastases or increased risk of brain metastases, will be assessed at 3 time points: before the treatment, immediately after the treatment, and on the next follow up visit. the assessment tools that will be used are neurotrax standard cognitive computerized tests and 2 short questionnaires.patients that will receive a one-day treatment will be tested on 2 time points only- before the treatment and on fu.the research will reveal the positive and the negative influences of the radiotherapy, along with the assessment of norms for the cognitive function and quality of life of oncologic patients being treated by rt.eligibility criteria:oncologic patients of both genders, with primary brain tumors, metastases or with increased risk of brain metastases, that are referred to conformal/palliative or preventive radiotherapy treatment or to stereotactic radiosurgery, who are able to follow instructions in hebrew.the participants will be 20-80 years old.main comparisons will be performed between the cognitive tests results on 3 time points mentioned. the study will continue until the needed number of participants will be achieved.

Eligibility criteria:
inclusion criteria: * 20-80 years old oncologic patients, of both genders, that are referred to brain radiotherapy or stereotactic radiosurgery due to primary brain tumor/ brain metastases or increased risk for brain metastases. * are able to follow instructions in hebrew. exclusion criteria: * non-hebrew speakers can not participate.

Keywords: psychology
a randomized controlled trial comparing the effect of pelvic floor muscle training

Conditions: Pelvic Floor Muscle Weakness

Summary: aim: to determine the effects of pelvic floor muscle training (pfmt) in women with a single delivery route. pregnancy and delivery route alter the pelvic floor muscle strength and are considered risk factors for urinary incontinence and genital dystopias. methods: a randomized controlled clinical trial with two hundred ninety-seven women aged 35 to 45 years old were selected for functional assessments of their pelvic floors by vaginal digital palpation and perineometry. one hundred sixty-five (69.7%) exhibited muscle strength deficits and were included in the clinical trial. the participants were distributed into two groups based on the delivery route (a, vaginal delivery and b, cesarean delivery) and were then randomly subdivided into groups a1 (n = 44) and b1 (n = 42), who performed pfmt, and groups a2 (n = 39) and b2 (n = 40), who did not undergo muscle training. the pfmt involved perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions. the functional assessment of pelvic floor by vaginal digital palpation and perineometry was performed after 15 sessions of pelvic´s floor muscles training. the statistical analysis was performed using the mann-whitney and z tests at a 5% level of significance.


Eligibility criteria:
inclusion criteria: * age between 35 and 45 years old, obstetric antecedent of a single delivery route (i.e., vaginal or abdominal), and regular menstrual cycles for six months prior to the initial interview. exclusion criteria: * women who had complaints or clinical manifestations suggestive of urinary incontinence, intense pelvic or vaginal pain, past histories of physical therapy for pelvic floor strengthening, correction of genital prolapse, myomectomy, (total or subtotal) hysterectomy, morbidities such as diabetes and arterial hypertension, or body mass indices (bmis) that were determined during the physical examination to be equal to or higher than 30 kg/m2.

Keywords: pregnancy pelvic floor muscle strength exercise therapy natural childbirth cesarean section physiotherapy
continuos terlipressin infusion in septic shock

Conditions: Septic Shock

Summary: the purpose of this study is to evaluate the efficacy of terlipressin for treating septic shock.

septic shock is the most common cause of death in intensive care units and has a mortality rate of 40 to 60%.vasopressin is commonly used as an adjunct to catecholamines to support blood pressure in refractory septic shock.recently small sample clinical study suggest that terlipressin,a vasopressin analogues, was effective in reversing sepsis-induced arterial hypotension and in reducing norepinephrine requirements.but its effect on mortality is unknown.invesgators hypothesized that terlipressin as compared with norepinephrine would decrease mortality among patients with septic shock.

Eligibility criteria:
inclusion criteria: * septic shock was defined by the presence of two or more diagnostic criteria for the systemic inflammatory responsesyndrome, proven or suspected infection, and hypotension (exclusion of hypertention other than sepsis) exclusion criteria: * organ transplantation; * pregancy or breast-feeding; * malignancy or other irreversible disease or condition for which has a poor prognosis; * acute coronary syndrome; * chronic heart failure(nyha iii or iv)/cardiogenic shock; * acute mesenteric ischemia; * greater than 48 hours had elapsed since the patient met entry criteria; * estimation of incomplite treament due to financial problem; * use of terlipressin for blood pressure support before entry; * raynaud's phenomenon, systemic sclerosis or vasospastic diathesis; * registration of other clinical trial which will affect the outcome of the current study
screening of patients admitted to a local hospital with pocket-sized ultrasound

Conditions: Heart Disease; Dyspnea; Aortic Disease; Kidney Disease; Liver Disease

Summary: ultrasound (us) is widely used as a diagnostic tool in a hospital setting. in a medical department, diagnosis like heart failure or most kinds of heart diseases, hypervolemia, hypovolemia, pleural effusion, pericardial effusion, ascites, diseases in the gall bladder/bile tract, urine tract and venous thrombosis are common. us is the key diagnostic tool in these diagnosis, and on early diagnosis is crucial both on behalf of the patients well-being, and for hospital logistic reasons. 1. the aim is to study the clinical use of pocket sized us as a screening diagnostic tool in an department of internal medicine. method: all patients admitted (in certain preset periods) to department of medicine will be screened with pocket sized us by expert user. changes in diagnoses, as well as medications as a result of us screening will be the endpoints. us findings will be validated against standard echocardiography, or standard us/ct/mri performed at the radiological department. 2. the aim is to study the clinical use of pocket sized us as a screening diagnostic tool in a department of cardiology. method: all patients admitted (in certain preset periods) to department of cardiology will be screened with pocket sized us for heart disease, pericardial and pleural effusion. examinations by expert users. specific findings could be myocardial dysfunction as heart failure, cardiomyopathies, regional dysfunction due to ischemia, valvular dysfunction, atrial enlargement, and pleural/pericardial effusion. changes in diagnoses, as well as medications as a result of us screening will be the endpoints. us findings will be validated against standard echocardiography in all. 3. as in 1), but examination by non-expert users compared to expert users.


Eligibility criteria:
inclusion criteria: * patients admitted to dep. of medicine at levanger hospital exclusion criteria: * not able to give informed consent

Keywords: echocardiography heart failure kidney lung aorta
evaluation of pain regression in patients with myofascial facial pain using dextrose, local anaesthesia and saline.

Conditions: Myofascial Pain Syndrome

Summary: the aim of this study is to compare the treatment effects of dextrose prolotherapy, saline, and mepivacaine for deactivating myofascial trigger points within the jaw muscles.


Eligibility criteria:
inclusion criteria: - 1. presence of active myofacial pains in jaw muscles, previously identified by manual palpation. 2. age ≥ 18 years. 3. willingness to follow instructions exclusion criteria: * 1. therapeutic intervention for myofascial pain within the past month before the study, such as using of medications for pain control or wearing of occlusal splint. 2. clinical conditions such as pregnancy. 3. medical problems that may interfere with the procedures such as bleeding disorders, trigeminal neuralgia. 4. recent facial or neck trauma; medication or adjunctive treatment (eg, physiotherapy) that could not be stopped during the study; or allergy to local anesthetic solutions. 5. cognitive impairment or exhibited inadequate cooperation.
resiliency training in adolescents with nf1 and nf2

Conditions: Neurofibromatoses

Summary: this randomized controlled trial for resiliency training in adolescents with neurofibromatosis 1 and neurofibromatosis 2 via secure live video to determine the efficacy two stress and symptom management programs. both programs are 8 week group programs.

neurofibromatosis (nfs) are rare genetic conditions with cure. adolescents with nf experience more symptoms of depression and anxiety, higher levels of stress associated with coping with nf symptoms, lower levels of self esteem, difficulties with social skills and social support, high rates of learning disabilities, and more pain as compared with the general population norms. the aims of this study are to compare the effect of two stress and symptom management programs tailored for adolescents with neurofibromatosis on quality of life and psychosocial functioning. we will also examine the degree to which treatment-dependent improvements in quality of life are mediated by improvements in depression, pain intensity and pain interference.

Eligibility criteria:
inclusion criteria: * has a diagnosis of nf1 or nf2 and is between the ages of 12-17 * is capable of completing and fully understanding the informed consent process/assent and the study procedures and assessments in english; has parental approval for participation * english speaking and at least a 3rd grade self-reported and parent reported reading level * self reported/parent reported difficulties coping with stress and nf symptoms exclusion criteria: * has major medical co-morbidity not nf related expected to worsen in the next 12 months * recent (within past 3 months) change in antidepressant medication * recent participation in cognitive behavioral therapy or relaxation therapy (within past 3 months) * has significant mental health diagnosis requiring immediate treatment (e.g., untreated bipolar disorder, psychotic disorder, active substance dependence) * unable or unwilling to complete assessments electronically via redcap * unable or unwilling to participate in group videoconferencing sessions * unable or unwilling to participate along with at least 1 parent in a video screening session
lifestyle and obesity

Conditions: Obesity

Summary: the objective of this trial is to determine the effect of different lifestyle interventions such as aerobic exercise and alternative resistance training methods, combined with a hypocaloric diet, on weight, body composition and metabolic risk factors in overweight and obese adults.


Eligibility criteria:
inclusion criteria: * body mass index \> 24.9 kg/m² * age \> 18 y * pre-menopauzal exclusion criteria: * body mass index \> 40 kg/m² * pregnancy * diabetes * joint replacement surgery
prophylactic use of peg-rhg-csf in medium-high risk of fn in chemotherapy of breast cancer

Conditions: Febrile Neutropenia

Summary: this clinical study is a multiple center, registering and real-world conditional research. the breast cancer patients planning for chemotherapy evaluated with medium-high risk of febrile neutropenia (fn) are recruited, receiving the first level prophylactic use of peg-rhg-csf or the second level prophylactic use of peg-rhg-csf in at least two cycles of chemotherapy according to real-world clinical judgement and choice by physicians in local cancer center. comparing real conditional-fn rate, fn-caused hospitalization rate and antibiotic use rate, direct/indirect medical cost.

the breast cancer patients planning for neo-adjuvant/adjuvant chemotherapy evaluated with medium-high risk of febrile neutropenia (fn) according to nccn and asco guideline are recruited, receiving the first level prophylactic use of peg-rhg-csf or the second level prophylactic use of peg-rhg-csf according to real-world clinical judgement and choice by physicians in local cancer center for at least two cycles of chemotherapy. the primary outcome is fn rate, the second outcomes are rate of 3-4 grade decrease of anc, fn-caused hospitalization, fn-caused antibiotic use rate, rate of reduction of chemotherapy dose, delay of chemotherapy, safety and pharmacoeconomics.

Eligibility criteria:
inclusion criteria: 1. provision of informed consent 2. stage i-iii, invasive breast cancer 3. accept at least 4 cycles of chemotherapy 4. ecog score 0-2 5. with medium-high risk of fn according to researchers exclusion criteria: 1. accepted stem cell or bone marrow transplant 2. undergoing any other clinical trial 3. uncontrolled infection, temperature≥38℃ 4. per-week scheme chemotherapy 5. concurrent with radiotherapy 6. allergic conditions 7. sever organ dysfunction 8. uncontrolled diabetes

Keywords: breast cancer chemotherapy peg-rhg-csf prophylactic febrile neutropenia
the use of cyanoacrylate on palatal wound

Conditions: Gingival Recession

Summary: the palatal donor site of autogenous free gingival grafts significantly influences the patient's morbidity. the purpose of this study was to evaluate the efficacy of cyanoacrylate on palatal wound healing and postoperative complaints.

a total of 35 patients were included in the study. in the test group (19 patient), cyanoacrylate was placed over the palatal wounds; conversely, the 16 control group patients were allowed to heal in a conventional way without cyanoacrylate. primary bleeding time, presence of secondary bleeding, postoperative pain and completion of epithelization were assessed following free gingival graft operation. as a result, compared to the control group it was determined that the cyanoacrylate tissue adhesive could reduce the postoperative morbidity and improve the wound healing.

Eligibility criteria:
inclusion criteria: * no systemic diseases * no coagulation disorders * no drug intake in the previous 6 months that might effect the periodontal health status * no pregnancy or lactation * no smoking habit * \<1 mm attached gingiva width on one or two lower anterior teeth * miller class i- ii- iii (miller 1985) with deep gingival recession (˃ 3mm) exclusion criteria: * hematologic disorders * no cooperation
nasal antisepsis for c. auris prevention

Conditions: Candida Auris Infection; Colonization, Asymptomatic

Summary: this is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of candida auris.

the investigators will assess the effect of nasal antisepsis with 10% povidone iodine on nasal and skin colonization and environmental contamination with c. auris. this topical, widely used antiseptic agent is available over the counter in the u.s. it was chosen for its excellent safety profile, history as a nasal antiseptic for staphylococcus aureus decolonization, proven in vitro activity against c. auris and feasibility in acute care and nursing home populations. this study will be conducted at 2 long-term acute care hospitals and one acute care hospital in the chicago, il region. participants will first undergo intranasal screening for current c. auris colonization. participants who grow c. auris from an anterior nares sample will be assigned 1:1 at random to receive intranasal povidone iodine (10% povidone iodine twice daily for up to 5 days) or control (no intranasal treatment). the investigators will perform all study visits during the participants' hospitalization at a participating facility. samples will be collected on 5 days during the intervention week, then once weekly thereafter. participants may participate for up to 8 study visits after randomization or until facility discharge, whichever occurs sooner.

Eligibility criteria:
inclusion criteria: * history of c. auris colonization or infection * patient in a participating facility exclusion criteria: * history of severe allergy to iodine-based products, defined as anaphylaxis or rash * currently breastfeeding or pregnant * non-english language speaking

Keywords: candida auris decolonization colonization infection prevention povidone iodine long-term care
real world evidence on the use of medical cannabis in pediatrics

Conditions: Cancer; Epilepsy; Neurodevelopmental Disorders

Summary: can-rwe is an observational study that is following 500 children who have authorizations for medical cannabis for two years from across canada.

pediatric patients (3 to 17 years) using medical cannabis (mc) for pain, sleep, mood, behaviour, seizures, treatment of cancer, or to manage symptoms related to cancer or cancer-treatment are eligible to join this 24-month study if they have a valid mc authorization. following screening, eligible participants will be contacted by the study coordinator. following informed consent, study participants will record complete outcome measures on pain, sleep, mood (anxiety, depression and positive affect), behaviour, as well as report their cannabis use and indication-specific outcomes as applicable at 3, 6, 12, and 18 weeks, as well as 6, 12, 18 and 24-months.

Eligibility criteria:
inclusion criteria: * 3 to 17 years * have a medical document provided by a prescribing health care practitioner (i.e. physician, nurse practitioner, etc.) for the use of medical cannabis * medical cannabis is authorized for pain, sleep, mood, behaviour, seizures, cancer or cancer-treatment related symptom management * ability to respond to electronic questionnaires in english exclusion criteria: * individuals using cannabis for medical purposes without a medical cannabis authorization from a health care provider * those only using cannabis recreationally

Keywords: cannabinoids cannabis pediatrics
how can we treat photophobia in migraine

Conditions: Migraine Disorders; Photophobia

Summary: photophobia, the aberrantly increased sensitivity to light, is a common symptom in migraine patients and light discomfort is frequently found as a trigger for migraine attacks. in behavioral studies, planned exposure to light was found to reduce headache in migraineurs with photophobia, potentially by increasing habituation to this migraine trigger. here, neurophysiological mechanisms of light exposure versus light deprivation therapy in migraine patients are investigated using functional magnetic resonance imaging (fmri). migraine patients and healthy controls receive light exposure therapy (flash) and light deprivation therapy (dark) for one hour daily on 7 consecutive days, in a crossover design with a wash-out period of three months. study participants keep a diary including items on interictal and ictal photophobia, headache frequency and severity 7 days before, during, and 7 days after the interventions. one week before and one day after both interventions, fmri using flickering light in a block design is applied. functional activation is analyzed at whole-brain level and habituation of the visual cortex (v1) is modeled with the initial amplitude estimate and the corrected habituation slope.


Eligibility criteria:
inclusion criteria: patients: * migraine without aura according to the criteria of the international classification of headache disorders (ichd-3 beta) * 1-4 days with migraine per month in the preceding last 3 months * a score between 2 and 6 on a numeric rating scale for the intensity of interictal photophobia (range from 0 to 10 (= max. intensity)) * a score \>4 for ictal photophobia controls * no personal or family history of migraine * a score \<2 for photophobia exclusion criteria: * current or previous circadian rhythm disorders * current or previous major depression * current or previous anxiety disorders * current or previous medication overuse * besides migraine in the patient group, participants should not suffer from any other recurrent headache apart from infrequent tension-type headaches

Keywords: migraine photophobia habituation headache functional magnetic resonance imaging